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Available online 3 January 2016The KCL034 human embryonic stem cell linewas derived from a normal healthy blastocyst donated for research.
The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the
derivation and cell line propagation were performed in an animal product-free environment and under current
Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed
by in vitro assays. The line was also validated for sterility, speciﬁc and non-speciﬁc human pathogens.
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Tathics The hESC line KCL034 is derived under licence from the UK
Human Fertilisation and Embryology Authority (research li-
cence numbers: R0075 and R0133) and also has local ethical
approval (UK National Health Service Research Ethics Commit-
tee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the
experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report. No ﬁnan-
cial inducements are offered for donation.2. Resource detailsonsent signedpluripotenc
rhodamineMay 26, 2009
mbryo thawed Jul. 11, 2011
K Stem Cell Bank
Deposit ApprovalMar. 08, 2012
Reference: SCSC12-54x Male 46, XY
rade Clinical
isease status Healthy/unaffected
aryotype (aCGH) No copy number changes detected.
P Array Gain in region 6p22.1 (Canham et al., 2015)NA ﬁngerprint
Allele sizes (in bp) of 16 microsatellite
markers speciﬁc for chromosomes 13, 18
and 21 (Jacquet et al., 2013)LA typing
HLA-A 11,29; B 44,51; Bw 4; C 04,16;
DRB1 04,07; DRB4 01; DQB1 02,03
(Jacquet et al., 2013; Canham et al., 2015)iability testing Pass
ycoplasma Negative
erility Pass
luripotent markers
(immunostaining)
(Fig. 1)NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityree germ layers
differentiation in vitro
(immunostaining)
(Fig. 2)Endoderm: AFP
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)ree germ layer
differentiation in vivo
(teratomas) (Fig. 3)Endoderm: AFP, GATA4
Ectoderm: TUBB3, GFAP (glial ﬁbrillary acidic
protein)
Mesoderm: DES (desmin), Alcian Blue and periodic
acid–Schiff (PAS)-stained cartilagey markers. Pluripotency is conﬁrmed by immunostaining (Oct4, N
–phalloidin (red), are present in both feeders and hES cell coloniergeted differentiation
(Fig. 4)anog, TRA-1-60, TRA-1-81) a
s, whereas AP activity (greenEndoderm: deﬁnitive endoderm — GATA4
(Cvoro et al., 2015).
Ectoderm: keratinocytes — p63, KRT14
(Petrova et al., 2014)
Mesoderm: cardiomyocytes — TNNT2bling lines available KCL032, KCL033SiWe generated KCL034 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation
potential into three germ layers was veriﬁed in vitro (Fig. 2), in vivo
(Fig. 3) and with targeted differentiation into speciﬁc endoderm, ecto-
derm and mesoderm cell types (Fig. 4).
Molecular karyotyping identiﬁed a gain on chromosome6p22.1. The
gain on chromosome 5p14.3 containing the following genes:
HIST1H2BL, HIST1H2AI, HIST1H3H, HIST1H2AJ, HIST1H2BM, HIST1H4J,
HIST1H4K, HIST1H2AK, HIST1H2BN, HIST1H2AL, HIST1H1B, HIST1H3I,
HIST1H4L, HIST1H3J, HIST1H2AM, HIST1H2BO, OR2B2 and OR2B6
(Canham et al., 2015). The 330.8 kb gain starts at bp 27627265 and
ends at bp 27958049 as referred toHumanGenomeBuild 38. This dupli-
cation that contained part of the Histone 1 gene cluster was not fully
present on the database of genomic variants (DGV; http://dgv.tcag.ca),
which has collected structural variations in more than 14,000 healthy
individuals from worldwide population (MacDonald et al., 2014). It is
probable that this gain represents a benign event as other histone clus-
ters have been shown to be preferentially duplicated during evolution
(Canham et al., 2015; Braastad et al., 2004).
Validation for sterility and speciﬁc and non-speciﬁc human patho-
gens (Devito et al., 2014) conformed that the cells in Master Bank
were sterile, mycoplasma-free, and negative as well as for Treponema
pallidum, Chlamydia, Neisseria gonorrhoeae, Human immunodeﬁcien-
cy virus-1 and 2 (HIV-1 and -2), Human T-lymphotropic virus type-1
and 2 (HTLV-1 and 2), Hepatitis A, B and C (HAV, HBV and HCV),
Human herpes simplex virus HHV-4 (Epstein–Barr virus, EBV), -6, -7,
and -8, Human cytomegalovirus (hCMV), human parvovirus B19,
SV40, JCV, BKV, Enterovirus, HAV, HCV, nonspeciﬁc viral and other ad-
ventitious contaminants.
We also generated research grade of KCL034 line that is adapted to
feeder-free conditions.nd alkaline phosphatase (AP) activity assay. Actin stress
) is detected only in hES cells. Scale bar, 50 μm.
Fig. 2. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm and α-
fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
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3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in meantime new versions of PIS/consent are imple-
mented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (FRO-V.6) were created on Dec. 18, 2008.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 7 — R.4 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on May 26, 2009. HFEA Code of Practice
that was in effect at the time of donor signature: Edition 7 — R.4. HFEA
Code of Practice Edition 7 — R.4 was in effect: 02 Oct. 2008–30 Sep.
2009.
3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).Fig. 3. Differentiation of three germ layers in vivo. Teratomas were encapsulated and did not
speciﬁc stains are brown (immunohistochemistry) or light blue (Alcian blue). Germ layer m
ectoderm, GATA4 and AFP for endoderm. Positive immunostaining for complex IV type II m
desmin). Scale bars are 100 μm.3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed
mechanically from outgrowth (Ilic et al., 2007, 2010). hES colonies
were expanded and cryopreserved at the third passage.
3.4. Viability test
Strawswith the earliest frozen passage (p. 2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
3.5. Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
3.6. Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo as described (Petrova et al., 2014; Stephensoninvade surrounding tissue. Sections are counterstained with hematoxylin and eosin and
arkers: Alcian blue–PAS-stained cartilage and DES for mesoderm, TUBB3 and GFAP for
arker conﬁrms the human origin of the tumor (adjacent section of the one stained for
Fig. 4. Targeted differentiation into speciﬁc cell types of endoderm (deﬁnitive endoderm), extoderm (keratinocytes) andmesoderm (cardiomyocytes). Deﬁnitive endoderm:GATA2 (red),
nuclei (blue). Ectoderm: p63 (red), KRT14 (green), nuclei (blue). Mesoderm: TNNT2 (green), nuclei (blue). Scale bar, 125 μm.
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2015; Laﬂamme et al., 2007) and deﬁnitive endoderm (Cvoro et al.,
2015; Cheng et al., 2012), keratinocytes (Petrova et al., 2014), followed
the protocols described earlier. Nuclei are visualized with Hoechst
33342.
3.7. Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.8. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
3.9. Whole-genome single nucleotide polymorphism (SNP) array
SNP array was performed as described in details (Canham et al.,
2015).
3.10. HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS)
Pathology (Guy's Hospital, London, UK) as described (Jacquet et al.,
2013). HLA typing was also performed independently by other group
(Canham et al., 2015).
3.11. Validation for sterility and speciﬁc and non-speciﬁc human pathogens
Validation for sterility and speciﬁc and non-speciﬁc human patho-
gens was performed as described (Devito et al., 2014). All validation
studies were conducted by SGS Vitrology (Glasgow, U.K., http://www.
sgs.com), in compliance with the principles of GMP as set out in Direc-
tive 2003/94/EC for medicinal products for human use (Directive
2003/94/EC, 2003) and 91/412/EEC for veterinary medicinal products
(Directive 91/412/EEC, 1991).
Sterility testing was performed in accordance with the current re-
quirements of the European Pharmacopoeia, Section 2.6.1 Sterility,
U.S. Pharmacopeia, 71. Sterility Tests, and International Conference on
Harmonisation Topic Q5D guidelines.
Mycoplasma testing was performed in accordance with the cur-
rent requirements of the European Pharmacopoeia, Section 2.6.7,
Mycoplasmas.All PCR-based assays used were compliant with the current edition
of the European Pharmacopoeia, 2.6.21, Nucleic Acid Ampliﬁcation
Techniques.
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